Cardiol Therapeutics Inc Class A (CRDL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has a cash flow conversion efficiency ratio of -0.292x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-5.23 Million ≈ $-3.78 Million USD) by net assets (CA$17.88 Million ≈ $12.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CRDL market cap overview for the company's overall valuation and market capitalisation.
Cardiol Therapeutics Inc Class A - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Cardiol Therapeutics Inc Class A's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cardiol Therapeutics Inc Class A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their cash flow conversion efficiency. See Cardiol Therapeutics Inc Class A (CRDL) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
0.014x |
|
Brogent Technologies
TWO:5263
|
0.036x |
|
Grupo Aeroméxico, S.A.B. de C.V.
NYSE:AERO
|
-0.312x |
|
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
-0.116x |
|
Latécoère S.A.
PA:LAT
|
0.109x |
|
Maritime Resources Corp.
V:MAE
|
0.038x |
|
Scicom MSC Bhd
KLSE:0099
|
0.047x |
|
Guolian Securities Co. Ltd
F:34V
|
0.259x |
Annual Cash Flow Conversion Efficiency for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual cash flow conversion efficiency of Cardiol Therapeutics Inc Class A from 2017 to 2025. View CRDL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$17.88 Million ≈ $12.93 Million |
CA$-23.85 Million ≈ $-17.26 Million |
-1.334x | -31.66% |
| 2024-12-31 | CA$24.73 Million ≈ $17.89 Million |
CA$-25.06 Million ≈ $-18.13 Million |
-1.013x | -13.68% |
| 2023-12-31 | CA$28.25 Million ≈ $20.43 Million |
CA$-25.18 Million ≈ $-18.22 Million |
-0.891x | -70.96% |
| 2022-12-31 | CA$52.20 Million ≈ $37.76 Million |
CA$-27.22 Million ≈ $-19.69 Million |
-0.521x | -68.80% |
| 2021-12-31 | CA$76.24 Million ≈ $55.15 Million |
CA$-23.55 Million ≈ $-17.04 Million |
-0.309x | +55.37% |
| 2020-12-31 | CA$13.27 Million ≈ $9.60 Million |
CA$-9.19 Million ≈ $-6.64 Million |
-0.692x | +10.76% |
| 2019-12-31 | CA$14.67 Million ≈ $10.61 Million |
CA$-11.38 Million ≈ $-8.23 Million |
-0.776x | -58.59% |
| 2018-12-31 | CA$22.27 Million ≈ $16.11 Million |
CA$-10.89 Million ≈ $-7.88 Million |
-0.489x | -8.02% |
| 2017-12-31 | CA$2.85 Million ≈ $2.06 Million |
CA$-1.29 Million ≈ $-934.75K |
-0.453x | -- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more